Liscure

Developer of bacteria-mediated immunotherapeutic drugs for multiple diseases

placeSeoul, Seoul, South Korea calendar_todayFounded 2018 groups7 employees language liscure.bio

Registered entities

Investor mix

3 investors on record; lead investors include NHN Investment, Shinhan Financial Group, KB Securities.

Investor typeCountShare
Venture capital133%
Other / undisclosed267%
Coming soon